{"id":474037,"date":"2020-03-16T10:32:01","date_gmt":"2020-03-16T10:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=474037"},"modified":"2020-03-16T10:32:01","modified_gmt":"2020-03-16T10:32:01","slug":"osteosarcoma-market-insights-market-trends-market-forecast-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/osteosarcoma-market-insights-market-trends-market-forecast-2030_474037.html","title":{"rendered":"Osteosarcoma Market Insights, Market trends, Market Forecast 2030"},"content":{"rendered":"
\"Osteosarcoma<\/a><\/p>\n
\n
Osteosarcoma is more common in males than in females. Females tend to develop it slightly earlier.<\/div>\n<\/div>\n<\/div>\n
Osteosarcoma (also called osteogenic sarcoma) is the most common type of cancer that starts in the bones. The cancer cells in these tumors look like early forms of bone cells that normally help make new bone tissue, but the bone tissue in an osteosarcoma is not as strong as that of normal bones.\n<\/div>\n

Albany, US –<\/strong> DelveInsight launched its new report on Osteosarcoma Market Insights, Epidemiology, and Market Forecast 2030<\/span><\/span>
<\/a><\/p>\n

DelveInsight’s “Osteosarcoma Market Insights, Epidemiology, and Market Forecast-2030″<\/span> report delivers an in-depth understanding of the Osteosarcoma, historical and forecasted epidemiology as well as the Osteosarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the report:<\/strong>
1. Osteosarcoma (OS) is a relatively rare tumour of bone with a worldwide Prevalence of 3.4 cases per million people per year<\/span>
2. Approximately 800 to 900 new cases of Osteosarcoma are diagnosed in the U.S. every year.<\/span>
3. About 2% of childhood cancers are osteosarcomas, but they make up a much smaller percentage of adult cancers.<\/span><\/p>\n

Key benefits of the report:<\/strong>
1. Osteosarcoma market report covers a descriptive overview and comprehensive insight of the Osteosarcoma epidemiology and Osteosarcoma market in the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.<\/span>
2. Osteosarcoma market report provides insights on the current and emerging therapies.<\/span>
3. Osteosarcoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/span>
4. Osteosarcoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Osteosarcoma market.<\/span><\/p>\n

Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/osteosarcoma-market<\/span><\/p>\n

“The World Health Organization’s histologic classification of bone tumors divides OS into Central, Intramedullary and Surface tumors.”<\/strong><\/p>\n

\"\"<\/p>\n

Stages of osteosarcoma<\/strong>:
• Localized-The tumour is only in the bone where it began and in the tissue around it. The tumour has not detectably spread to other parts of the body.
• The metastatic-The tumour has spread from the bone where it began to another part of the body. Most often, it spreads to the lungs or other bones.
• Recurrent-Recurrent osteosarcoma is a tumour that has come back during or after treatment. It can come back to the same place where it started or in another part of the body. Osteosarcoma recurs most often in the lungs and rarely other bones. If there is a recurrence, cancer may need to be staged again. This is called re-staging.<\/p>\n

The key pharma players in Osteosarcoma market<\/strong> are:
1. Eleison Pharmaceuticals
2. Aadi Bioscience
3. Cellectar Biosciences
<\/span><\/p>\n

Emerging <\/strong>Drugs<\/strong>:
1. Inhaled lipid-complexed cisplatin
2. ABI-009
3. CLR 131<\/p>\n

Request a free sample report<\/strong> @https:\/\/www.delveinsight.com\/sample-request\/osteosarcoma-market<\/p>\n

Table of contents<\/strong>
1. Report Introduction<\/span>
2. Osteosarcoma Market Overview at a Glance<\/span>
3. Osteosarcoma Disease Background and Overview<\/span>
4. Osteosarcoma Epidemiology and Patient Population<\/span>
5. Osteosarcoma Country- Wise Epidemiology<\/span>
5.1. United States<\/span>
5.2. EU-5<\/span>
5.2.1.Germany<\/span>
5.2.2.France<\/span>
5.2.3.Italy<\/span>
5.2.4.Spain<\/span>
5.2.5.United Kingdom<\/span>
5.3. Japan<\/span>
6. Osteosarcoma Treatment & Medical Practices<\/span>
7. Osteosarcoma Emerging Therapies<\/span>
7.1. Key Cross Competition<\/span>
7.2. Inhaled lipid-complexed cisplatin: Eleison Pharmaceuticals<\/span>
7.3. ABI-009: Aadi Bioscience<\/span>
7.4. CLR 131: Cellectar Biosciences<\/span>
8. Osteosarcoma Market Size<\/span>
9. 7MM Osteosarcoma Country-Wise Market Analysis<\/span>
9.1. United States<\/span>
9.2. Germany<\/span>
9.3. France<\/span>
9.4. United Kingdom<\/span>
9.5. Spain<\/span>
9.6. Italy<\/span>
9.7. Japan<\/span>
10. Osteosarcoma Report Methodology<\/span>
11. DelveInsight Capabilities<\/span>
12. Disclaimer<\/span>
13. About DelveInsight<\/span><\/p>\n

Related Reports: <\/strong><\/p>\n

Osteosarcoma – Epidemiology Forecast to 2030<\/span><\/a><\/p>\n

Osteosarcoma Pipeline Insight, 2020<\/span><\/a><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Yash Bhardwaj
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> NEVADA 89107
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Osteosarcoma is more common in males than in females. Females tend to develop it slightly earlier. Osteosarcoma (also called osteogenic sarcoma) is the most common type of cancer that starts in the bones. The cancer cells in these tumors look … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,413,404],"tags":[],"class_list":["post-474037","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/474037","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=474037"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/474037\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=474037"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=474037"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=474037"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}